Welcome to our dedicated page for CHARLES RIVER LABORATORIES INTERNATIONAL SEC filings (Ticker: CRL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CHARLES RIVER LABORATORIES INTERNATIONAL's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CHARLES RIVER LABORATORIES INTERNATIONAL's regulatory disclosures and financial reporting.
FMR LLC reports beneficial ownership of 4,239,751.47 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. common stock, representing 8.8% of the class as of June 30, 2026. FMR has sole voting power over 4,190,715.80 shares and sole dispositive power over 4,239,751.47 shares, with no shared voting or dispositive power.
Abigail P. Johnson is reported with sole dispositive power over the same 4,239,751.47 shares but no voting power. One or more other persons may receive dividends or sale proceeds from these shares, but no single person holds more than five percent of the outstanding common stock. Subsidiary details are referenced in an attached exhibit.
CRL has a Form 144 notice indicating a potential sale of up to 5,046 shares of common stock on the NYSE, with an aggregate market value of $1,327,098.00. The filing lists total common shares outstanding of 47,738,872. The sale, proposed for 08/05/2026, includes shares from performance stock awards granted on 01/27/2023 (3,511 shares) and 01/29/2024 (1,535 shares) by the issuer.
Charles River Laboratories International, Inc. reported second‑quarter 2026 revenue of $1.00 billion, down 2.7% from $1.03 billion a year earlier, while organic revenue edged up 0.1%. GAAP results swung to a small net loss of $(1.5) million, or $(0.03) per share, primarily due to a $63.7 million loss on the divestiture of its CDMO and Cell Solutions businesses.
On a non‑GAAP basis, operating margin was 20.5% versus 22.1% and net income declined 5.0% to $146.2 million, with diluted EPS of $3.02 compared with $3.12 in the prior‑year quarter. Segment results were mixed: RMS revenue was $209.5 million with organic revenue down 1.4%, DSA revenue was $606.5 million with organic growth of 0.2%, and Manufacturing revenue was $188.1 million, down 6.3% reported but up 1.3% organically.
The company repurchased $100.0 million of stock in the quarter and $300.0 million year‑to‑date, leaving $700.0 million under its $1.0 billion authorization. For 2026, it raised organic revenue growth guidance to 0.0%–1.0% and non‑GAAP EPS to $11.15–$11.45, while lowering GAAP EPS guidance to $3.05–$3.35 to incorporate divestiture‑related losses.
Charles River Laboratories director James C. Foster reported an open-market sale of 75,000 shares of common stock at $225.00 per share. The sale was executed pursuant to a Rule 10b5-1 Trading Plan adopted on March 6, 2026. After the sale, he holds 31,596 shares directly and additional indirect holdings through various trusts and GRATs.
CRL notified a proposed sale of 75,000 shares of Common Stock through UBS Financial Services. The filing lists an aggregate offering price of $16,875,000.00 and reports 48,167,730 shares outstanding as of 06/29/2026. The listing includes multiple RSU/PSU lots with grant and vesting dates and share counts.
Charles River Laboratories director James C. Foster reported exempt, bona fide gifts and related trust transfers of 366,722 shares of common stock dated 2026-06-05. The Form 4 shows these shares moving among his direct holdings, revocable trusts he controls, and trusts associated with his spouse, all at a stated price of $0.00 per share, indicating no sale proceeds. Following these transactions, Foster holds 106,596 shares directly and 155,611 shares indirectly through a trust, plus additional indirect positions of 20,000 shares in a 2026 GRAT, 10,780 shares in a 2025 GRAT, 5,423 shares in a 2024 GRAT, and 10,000 shares in a trust held by his spouse.
Charles River Laboratories' CEO Birgit Girshick reported exempt insider transfers primarily structured as gifts rather than market sales. She made bona fide gifts totaling 6,772 shares of Common Stock on June 5, 2026, including a transfer of 3,386 shares to a revocable trust she controls under Rule 16a-13.
Following these transfers, she holds 36,013 Common shares directly and 43,803 shares indirectly through the revocable trust. She also holds stock options covering 8,722 shares of Common Stock, exercisable at $208.44 per share and expiring on May 31, 2034. These transactions did not involve any sale proceeds.
Charles River Laboratories executive Shannon M. Parisotto, Chief Executive Vice President for Discovery & Safety Assessment, reported non-market movements in Common Stock. On June 5, 2026, she made bona fide gifts totaling 3,058 shares, with 1,529 shares transferred as an exempt move under Rule 16a-13 to a revocable trust she controls.
After these transactions, she holds 9,853 Common Stock shares directly, 9,680 shares indirectly through a trust, and 28,510 shares indirectly via Karpathos Investments LLC. All reported actions are gifts or internal reallocations, not open-market purchases or sales.
Barg Steven reported acquisition or exercise transactions in this Form 4 filing.
Charles River Laboratories director Steven Barg received an equity grant as part of his board compensation. He was awarded 422 shares of Common Stock in the form of restricted stock units at a reference price of $174.79 per share, bringing his direct holdings to 3,287 shares following the grant.
The grant was made in lieu of director service fees for the term beginning on May 5, 2026. These restricted stock units will vest on the earlier of June 2, 2027 or the business day before the company’s next annual meeting of shareholders, making this a routine, compensation-related, non-market transaction.